[New drugs for the treatment of constipation].
This review introduces new therapeutic options in the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Therefore, prucalopride and lubiprostone are discussed including their mechanisms and side effects. In addition, other substances that are currently under evaluation such as renzapride and linaclotide are described, since recent results showed a significant effect in patients with constipation. Thus, after the withdrawal of tegaserod due to cardiac side effects, new potent drugs are now available for the treatment of constipation.
Adam
Birgit
B
Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Essen, Germany. birgit.adam@uk-essen.de
Liebregts
Tobias
T
Gerken
Guido
G
D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use; D001572:Benzofurans / Q000009:adverse effects / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000009:adverse effects / Q000627:therapeutic use; D002400:Cathartics / Q000009:adverse effects / Q000627:therapeutic use*; D065101:Chloride Channel Agonists; D003248:Constipation / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000209:etiology; D000068238:Lubiprostone; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D050705:Receptors, Guanylate Cyclase-Coupled / Q000819:agonists; D044422:Receptors, Serotonin, 5-HT4 / Q000187:drug effects
D001549:Benzamides; D001572:Benzofurans; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002400:Cathartics; D065101:Chloride Channel Agonists; D010455:Peptides; C406662:prucalopride; D044422:Receptors, Serotonin, 5-HT4; D000068238:Lubiprostone; C053006:renzapride; D050705:Receptors, Guanylate Cyclase-Coupled; D000527:Alprostadil; C523483:linaclotide